查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1858131

成人血紅素血症檢測市場按檢測方式、疾病類型、最終用戶和分銷管道分類－全球預測，2025-2032年

Adult Hemoglobinopathy Testing Market by Modality, Disease Type, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，成人血紅素血症檢測市場規模將成長 81.4 億美元，複合年成長率為 6.01%。

關鍵市場統計數據
基準年 2024 51億美元
預計年份：2025年 54.1億美元
預測年份 2032 81.4億美元
複合年成長率 (%) 6.01%

確立加強成人血紅蛋白血症檢測在整個醫療服務體系和實驗室網路中的臨床和運作要務。

成人血紅素血症檢測處於臨床需求與診斷創新交會點，影響臨床醫師如何檢測、鑑別與管理成人族群中的遺傳性血紅素疾病。隨著人們對鐮狀細胞疾病和地中海貧血等疾病終身影響的認知不斷提高，臨床醫生和實驗室主任都面臨著對準確、及時且具有臨床指導意義的診斷結果日益成長的期望。因此，診斷路徑正從獨立的確認性檢測發展為多層次策略，整合表現型檢測、分子分析和標靶反射性方法，以最佳化患者照護並節省資源。

技術、臨床指南和報銷機制的不斷發展變化正在重新定義成人血紅蛋白血症檢測的實施和評估方式。

成人血紅蛋白血症檢測格局正在轉變，這主要得益於技術的成熟、醫療模式的改變以及支付方和監管機構優先事項的演變。分子方法（例如次世代定序和標靶基因分型）的進步使得血紅素變異體和複雜地中海貧血基因型的識別更加精準，促使實驗室從單一分析流程轉向結合蛋白質和DNA檢測方法的綜合診斷演算法。同時，即時檢測技術的改進正在分散初步篩檢，並使患者能夠更早獲得醫療服務，尤其是在集中式檢查室資源有限的地區。

2025年，不斷變化的貿易措施將如何重塑血色素沉著症檢測的診斷劑和設備採購、供應商策略以及成本動態？

2025年新關稅的實施正在影響成人血紅蛋白血症檢測中使用的檢查室耗材、診斷劑和照護現場設備的供應鏈、籌資策略和定價動態。由於關稅增加了進口設備和試劑的到岸成本，檢查室和醫療系統正在重新評估供應商合約和物流模式，以維持營運的連續性。為此，許多機構正在籌資策略多元化，尋求國內經銷商，並協商基於採購量的契約，以緩解短期成本壓力。這些轉變可能會對採購計畫和資本支出計畫產生連鎖反應，促使人們更加關注保存期限更長的試劑和能夠降低單次檢測成本的整合工作流程設備。

基於跨模式、疾病亞型、最終用戶和通路配置的細分，診斷和商業性意義

細緻的市場區隔方法能夠明確哪些領域的應用最有可能加速，以及哪些領域的針對性產品開發能夠帶來最大的臨床和商業性回報。根據檢測方式，市場可分為實驗室就地檢驗）。實驗室檢測又可細分為電泳、基因分析和高效液相層析），而就地檢驗包括專為分散式篩檢設計的快速檢測。這些檢測方式的差異也體現在診斷流程中：檢查室仍然依賴電泳和HPLC進行初步的蛋白質表徵，但擴大將基因分析整合到確診和困難病例的解決中。

區域診斷生態系統和採用梯度將決定全球市場中成人血紅蛋白血症檢測的優先順序和部署方式。

區域動態對成人血紅素血症檢測的採納模式、監管互動以及診斷生態系統的結構有顯著影響。在美洲，臨床基​​礎設施和成熟的檢查室網路促進了先進分子診斷技術和整合檢測流程的快速普及，而支付方的多樣性和區域報銷政策則造就了異質性的商業性環境，臨床效用的證明至關重要。因此，在醫療保健採購方要求明確療效相關性的市場中，能夠提供全面驗證方案和可靠上市後證據的供應商往往能更快獲得市場認可。

診斷公司為推動技術應用、保持差異化優勢以及確保供應和監管方面的韌性而採取的競爭與合作策略

診斷公司之間的競爭動態正朝著將檢測創新、服務交付和證據產生相結合的合作模式轉變。領先企業正投資於整合蛋白質分離方法、分子檢測和數位化報告的平台，使檢查室能夠簡化工作流程，並為臨床醫生提供統一的診斷結果。與學術中心和臨床網路建立策略夥伴關係正日益被用於產生真實世界證據、檢驗在不同患者群體中的效用，並加強醫療保險報銷對話和臨床指南的採納。同時，一些機構正在推行垂直整合策略以控制試劑品質和夥伴關係連續性，而其他機構則強調通路合作，以擴大地域覆蓋範圍並提升客戶支援。

製造商、實驗室和醫療系統可以採取哪些切實可行的策略步驟來加速診斷技術的普及應用、確保診斷服務的可及性並管理營運風險

致力於影響臨床實踐並獲取永續價值的產業領導者應採取一系列策略行動，將產品開發、臨床證據和客戶參與相結合。首先，透過投資模組化診斷解決方案來降低複雜性並提高診斷產量比率，使檢查室能夠在單一、可擴展的平台上整合基於蛋白質和基因的方法。其次，制定引人注目的價值主張和真實世界證據包，量化臨床效用和後續效益，以便與支付方和醫院採購委員會進行更有效的對話。第三，優先考慮供應鏈多元化和區域合作，以降低關稅造成的成本波動，並確保試劑和設備的持續供應。

採用嚴謹的混合方法，結合技術檢驗、相關人員參與和監管分析，以獲得可操作的診斷見解。

本分析的研究基礎是將同行評審文獻、監管文件和技術白皮書的全面審查與和臨床及實驗室專家的結構化訪談相結合，從而對診斷性能特徵和臨床效用進行三角驗證。數據綜合分析包括對檢測原理、技術完備等級和已記錄的臨床工作流程的分析，並輔以對實驗室主任、血紅蛋白病臨床醫生和供應鏈經理的訪談，以獲得營運方面的見解。在條件允許的情況下，分析準確性透過驗證和能力驗證結果進行評估，監管核准和指導文件則為合規要求提供了依據。

整合策略重點和臨床需求，以確定診斷如何在成人血紅素疾病治療中發揮持續價值。

成人血紅素血症檢測正處於曲折點，技術能力、臨床需求和經濟壓力都要求採用更整合、更具韌性且基於實證醫學的診斷策略。實驗室和醫療系統面臨越來越大的挑戰，需要在提供準確的基因型和表現型資訊的同時，應對貿易和供應鏈動態動態帶來的交付時間和成本壓力。因此，成功實施這些策略需要協調臨床工作流程和檢測方法的選擇，投資於實證醫學研究以支持支付者和指南的採納，並建立能夠預見監管和關稅變化的供應鏈策略。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 用於診斷成人血紅蛋白疾病的次世代定序技術的進展
  • 整合人工智慧主導的數位顯微鏡解決方案，實現成人血紅素病精準診斷
  • 利用微流體紙基分析儀擴大照護現場血色素沉著症檢測規模
  • 擴大高通量質譜技術在成人血紅素變異體全面分析的應用
  • 新興的非侵入性產前篩檢平台影響成人血紅素病風險評估
  • 開發一種針對成人族群中罕見血紅蛋白血症突變的多重PCR檢測方法
  • 增加遠距遠端醫療支援的遺傳諮詢服務，以管理成人血紅蛋白疾病
  • 監理核准對新型成人血紅素病診斷試劑盒商業化的影響

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 成人血紅素血症檢測市場（依檢測方式分類）

  • 實驗室檢測
    • 電泳
    • 基因分析
    • 高效液相層析
  • 就地檢驗
    • 快速檢測

9. 成人血紅素血症檢測市場（依疾病類型分類）

  • 血紅素C病
  • 鐮狀細胞性貧血症
  • 地中海型貧血
    • α地中海貧血
    • BETA-地中海型貧血
    • Delta貧血

第10章 成人血紅素血症檢測市場（依最終用戶分類）

  • 診斷實驗室
    • 醫院檢查室
    • 獨立測試機構
    • 參考檢驗機構
  • 醫院
    • 二級護理醫院
    • 三級醫院
  • 研究所

第11章 成人血紅素血症檢測市場（依分銷管道分類）

  • 直銷
  • 經銷商
    • 當地經銷商
    • 區域經銷商
  • 線上供應商

12. 成人血紅素血症檢測市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 成人血紅素血症檢測市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各國成人血紅素血症檢測市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Roche Diagnostics International AG
    • Thermo Fisher Scientific Inc.
    • Siemens Healthineers AG
    • Abbott Laboratories
    • Bio-Rad Laboratories, Inc.
    • Ortho Clinical Diagnostics Inc.
    • Danaher Corporation
    • Becton, Dickinson and Company
    • PerkinElmer, Inc.
    • Sysmex Corporation
Product Code: MRR-C002B1C99763

The Adult Hemoglobinopathy Testing Market is projected to grow by USD 8.14 billion at a CAGR of 6.01% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.10 billion
Estimated Year [2025] USD 5.41 billion
Forecast Year [2032] USD 8.14 billion
CAGR (%) 6.01%

Establishing the clinical and operational imperative for enhanced adult hemoglobinopathy diagnostics across care continuums and laboratory networks

Adult hemoglobinopathy testing sits at the intersection of clinical necessity and diagnostic innovation, shaping how clinicians detect, characterize, and manage inherited hemoglobin disorders in adult populations. As awareness of lifelong implications of conditions such as sickle cell disease and thalassemia increases, clinicians and laboratory directors alike face rising expectations for accurate, timely, and clinically actionable diagnostic results. Consequently, diagnostic pathways have evolved from singular confirmatory assays to layered strategies that integrate phenotypic testing, molecular analysis, and targeted reflex approaches that optimize patient care while conserving resources.

In parallel, health systems are recalibrating screening and care pathways to support adults who may have transitioned from pediatric services or who have undiagnosed conditions presenting later in life. This realignment emphasizes longitudinal management, genotype-informed therapy selection, and surveillance for disease complications. Therefore, stakeholders including laboratory managers, hospital systems, payers, and device developers must align clinical workflows with technological capabilities to ensure diagnostic results translate into improved outcomes. With these dynamics in mind, the following analysis synthesizes the major inflection points reshaping testing strategies, the regulatory and economic headwinds that can influence procurement and access, and pragmatic segmentation and regional considerations to guide clinical and commercial decision-making.

Unfolding technological, clinical guideline, and reimbursement shifts that are redefining how adult hemoglobinopathy testing is delivered and valued

The landscape of adult hemoglobinopathy testing is undergoing transformative shifts driven by technological maturation, changing care models, and evolving payer and regulatory priorities. Advances in molecular methods such as next-generation sequencing and targeted genotyping have enabled more precise discrimination among hemoglobin variants and complex thalassemia genotypes, and as a result laboratories are transitioning from single-analyte workflows toward integrated diagnostic algorithms that combine protein-based and DNA-based modalities. At the same time, improved point-of-care technologies are decentralizing initial screening and enabling earlier linkage to care, particularly in settings where access to centralized laboratories is constrained.

Concurrently, clinical practice guidelines and specialty societies are placing greater emphasis on genotype-informed therapeutic decisions, which elevates the diagnostic test from a confirmatory role to a decision-making instrument. Automation, digital laboratory information systems, and connected diagnostics are facilitating higher throughput and faster turnaround times, while data interoperability initiatives are enabling longitudinal patient tracking across care settings. Moreover, payer scrutiny and value-based contracting are incentivizing diagnostics that demonstrably reduce avoidable morbidity and downstream costs, prompting vendors to focus on evidence generation and real-world outcome studies. Taken together, these forces are reshaping who performs testing, where testing occurs, and how diagnostic value is defined and measured.

How evolving trade measures in 2025 are reshaping procurement, supplier strategies, and cost dynamics for diagnostic reagents and devices in hemoglobinopathy testing

The introduction of new tariff measures in 2025 is influencing supply chains, procurement strategies, and pricing dynamics for laboratory consumables, diagnostic reagents, and point-of-care devices used in adult hemoglobinopathy testing. When tariffs increase the landed cost of imported instrumentation and reagents, laboratories and health systems reassess supplier agreements and logistics models to maintain operational continuity. In response, many organizations are diversifying sourcing strategies, seeking domestic distributors, and negotiating volume-based contracts to mitigate short-term cost pressures. These shifts create ripple effects across procurement timetables and capital expenditure planning, and they can heighten interest in reagents with longer shelf lives or equipment that offers consolidated workflows to reduce per-test cost exposure.

In addition, diagnostic manufacturers and distributors adjust commercial strategies to protect market access and margins. Some vendors accelerate localization efforts, including regional assembly or partnering with local distributors to reduce tariff exposure. Others shift toward service-based models that emphasize reagent rental, managed inventory, and bundled support agreements that smooth cost volatility for customers. From a clinical perspective, payers and hospital procurement committees scrutinize test utilization and may tighten approval pathways for higher-cost assays, increasing the onus on diagnostic developers to demonstrate comparative clinical utility. Overall, the cumulative impact of tariffs is prompting stakeholders to prioritize supply chain resilience, pricing transparency, and evidence-based justification for adopting next-generation diagnostic solutions.

Segmentation-driven diagnostic and commercial implications across modalities, disease subtypes, end users, and distribution channel configurations

A nuanced segmentation approach clarifies where adoption is most likely to accelerate and where targeted product development will generate the greatest clinical and commercial return. Based on modality, the market separates into laboratory based tests and point of care tests, with laboratory based testing further differentiated into electrophoresis, genetic analysis, and high performance liquid chromatography, while point of care testing encompasses rapid tests designed for decentralized screening. These modality distinctions inform diagnostic pathways: laboratories continue to rely on electrophoresis and HPLC for initial protein-based characterization but are increasingly integrating genetic analysis for definitive diagnosis and complex case resolution, whereas rapid point-of-care tests serve as first-line screens that expedite referral to centralized confirmatory testing.

When viewed by disease type, the segmentation highlights distinct needs across hemoglobin C disease, sickle cell disease, and thalassemia, with thalassemia itself requiring sub-classification into alpha thalassemia, beta thalassemia, and delta thalassemia to reflect diverse genetic and clinical consequences. These disease-driven differences affect assay design, sensitivity requirements, and counseling support services. The end user segmentation further clarifies operational and purchasing behaviors: diagnostic laboratories, which include hospital laboratories, independent laboratories, and reference laboratories, make decisions based on throughput, certification requirements, and interoperability needs; hospitals composed of secondary care hospitals and tertiary care hospitals prioritize rapid turnaround and integration with clinical decision support; and research institutes focus on assay flexibility and depth of genotypic information for investigational studies. Finally, distribution channels-direct sales, distributors organized into local and regional distributors, and online vendors-shape commercial pathways and after-sales support expectations, influencing how manufacturers prioritize channel investments and training programs.

Regional diagnostic ecosystems and adoption gradients that determine how adult hemoglobinopathy testing is prioritized and deployed across global markets

Regional dynamics materially influence adoption patterns, regulatory interactions, and the structure of diagnostic ecosystems in adult hemoglobinopathy testing. In the Americas, clinical infrastructure and established laboratory networks facilitate rapid adoption of advanced molecular diagnostics and integrated laboratory workflows, while payer diversity and regional reimbursement policies create a heterogeneous commercial landscape where demonstration of clinical utility is paramount. Consequently, vendors that provide comprehensive validation packages and robust post-market evidence tend to gain traction more quickly in markets where institutional purchasers demand clear outcome linkages.

Europe, Middle East & Africa present a mosaic of regulatory regimes and healthcare capabilities where centralized reference laboratories coexist with emerging point-of-care deployment in under-resourced settings. Regulatory harmonization efforts and collaborative public health initiatives in some countries are accelerating screening and confirmatory testing programs, yet supply chain variability and local procurement practices require tailored go-to-market strategies. In Asia-Pacific, high-volume testing environments, strong domestic manufacturing capacity, and rapid uptake of decentralized diagnostics are shaping a competitive arena characterized by price sensitivity and technological innovation. Governments and health systems in the region are also investing in newborn and adult screening programs, which increases demand for scalable platforms and flexible service models. Across all regions, scaling diagnostics successfully requires alignment with local clinical guidelines, robust training for laboratory personnel, and logistics strategies adapted to regional supply chain realities.

Competitive and collaborative strategies that diagnostic firms adopt to drive adoption, sustain differentiation, and ensure supply and regulatory resilience

Competitive dynamics among diagnostic companies are shifting toward collaborative models that combine assay innovation with service delivery and evidence generation. Leading firms are investing in platforms that integrate protein-based separation methods with molecular assays and digital reporting, enabling laboratories to streamline workflows and present unified diagnostic outputs to clinicians. Strategic partnerships with academic centers and clinical networks are increasingly used to generate real-world evidence and to validate utility across diverse patient cohorts, strengthening reimbursement dialogues and clinical guideline adoption. In parallel, some organizations pursue vertical integration strategies to control reagent quality and supply continuity, while others emphasize channel partnerships to improve geographic reach and customer support.

Innovation focus is broadly centered on assay sensitivity, ease of use, and connectivity. Diagnostic developers that demonstrate interoperability with laboratory information systems and electronic health records find it easier to embed testing into clinical pathways. Moreover, companies that offer comprehensive training, proficiency testing, and lifecycle support secure stronger long-term relationships with institutional customers. Importantly, agility in regulatory submissions and post-market surveillance enables faster market access in jurisdictions with evolving approval frameworks. Overall, the competitive environment rewards firms that combine technical excellence with pragmatic commercial models and demonstrable clinical impact.

Practical strategic steps that manufacturers, laboratories, and health systems can take to accelerate adoption, secure access, and manage operational risk in diagnostics

Industry leaders seeking to influence clinical practice and capture sustainable value should pursue a coordinated set of strategic actions that align product development, clinical evidence, and customer engagement. First, invest in modular diagnostic solutions that allow laboratories to combine protein-based and genetic approaches within a single, scalable platform, thereby reducing complexity and improving diagnostic yield. Second, develop compelling value dossiers and real-world evidence packages that quantify clinical utility and downstream benefits, enabling more effective conversations with payers and hospital procurement committees. Third, prioritize supply chain diversification and regional partnerships to mitigate tariff-driven cost volatility and to ensure continuity of reagent and instrument availability.

Additionally, strengthen go-to-market models by tailoring distribution strategies to end user needs; this means offering turnkey services and training for hospital laboratories, specialized support for reference laboratories, and simplified deployment kits for point-of-care settings. Engage proactively with regulatory authorities and clinical guideline bodies to align test indications and reporting standards, and invest in digital integration to support longitudinal patient management and outcome measurement. Finally, build cross-functional teams that include clinical affairs, health economics, and customer success to translate scientific advances into adoption-ready solutions. These measures will position organizations to respond to evolving clinical demands while maintaining commercial agility.

A rigorous mixed-methods approach combining technical validation, stakeholder engagement, and regulatory analysis to derive practical diagnostic insights

The research underpinning this analysis combined a comprehensive review of peer-reviewed literature, regulatory filings, and technical white papers with structured engagements of clinical and laboratory experts to triangulate diagnostic performance characteristics and clinical utility considerations. Data synthesis included analysis of assay principles, technology readiness levels, and documented clinical workflows, supplemented by interviews with laboratory directors, clinicians specializing in hemoglobinopathies, and supply chain managers to capture operational realities. Where available, validation studies and proficiency testing results informed assessments of analytic accuracy, while regulatory approvals and guidance documents provided context on compliance requirements.

To ensure robustness, findings were cross-validated against multiple independent sources and subjected to scenario analysis exploring varied procurement, tariff, and adoption pathways. Stakeholder feedback loops were used to refine interpretation of technical trade-offs and to prioritize recommendations that are both clinically meaningful and operationally feasible. Throughout the research process, emphasis was placed on transparency of assumptions, reproducibility of analytic steps, and alignment with current practice standards to ensure that conclusions are actionable for decision-makers across clinical, laboratory, and commercial functions.

Synthesis of strategic priorities and clinical imperatives that will determine how diagnostics deliver durable value in adult hemoglobinopathy care

Adult hemoglobinopathy testing is at an inflection point where technological capability, clinical expectations, and economic pressures converge to demand more integrated, resilient, and evidence-based diagnostic strategies. Laboratories and health systems are increasingly challenged to deliver precise genotypic and phenotypic information while managing turnaround times and cost pressures amplified by trade and supply-chain dynamics. Therefore, successful implementation requires harmonizing assay selection with clinical workflows, investing in evidence generation to support payer and guideline adoption, and building supply chain strategies that anticipate regulatory and tariff-induced disruptions.

Moving forward, stakeholders who adopt a systems perspective-aligning product design, distribution models, and clinical validation-will be better positioned to meet patient needs and to sustain commercial viability. Strategic investments in interoperability, training, and regional partnerships will yield dividends in adoption and continuity of care. Ultimately, the diagnostic community's collective ability to translate analytic advances into demonstrable clinical benefits will determine how adult hemoglobinopathy testing contributes to improved patient outcomes and more efficient care delivery.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advances in next-generation sequencing assays for adult hemoglobinopathy diagnostics
  • 5.2. Integration of AI-driven digital microscopy solutions for accurate adult hemoglobinopathy diagnosis
  • 5.3. Expansion of point-of-care hemoglobinopathy testing using microfluidic paper-based analytical devices
  • 5.4. Growing adoption of high-throughput mass spectrometry for comprehensive adult hemoglobin variant profiling
  • 5.5. Emergence of noninvasive prenatal screening platforms impacting adult hemoglobinopathy risk assessment
  • 5.6. Development of multiplex PCR assays targeting rare hemoglobinopathy mutations in adult populations
  • 5.7. Increase in telemedicine-enabled genetic counseling services for adult hemoglobinopathy management
  • 5.8. Impact of regulatory approvals on commercialization of novel adult hemoglobinopathy diagnostic kits

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Adult Hemoglobinopathy Testing Market, by Modality

  • 8.1. Laboratory Based Tests
    • 8.1.1. Electrophoresis
    • 8.1.2. Genetic Analysis
    • 8.1.3. High Performance Liquid Chromatography
  • 8.2. Point Of Care Tests
    • 8.2.1. Rapid Tests

9. Adult Hemoglobinopathy Testing Market, by Disease Type

  • 9.1. Hemoglobin C Disease
  • 9.2. Sickle Cell Disease
  • 9.3. Thalassemia
    • 9.3.1. Alpha Thalassemia
    • 9.3.2. Beta Thalassemia
    • 9.3.3. Delta Thalassemia

10. Adult Hemoglobinopathy Testing Market, by End User

  • 10.1. Diagnostic Laboratories
    • 10.1.1. Hospital Laboratories
    • 10.1.2. Independent Laboratories
    • 10.1.3. Reference Laboratories
  • 10.2. Hospitals
    • 10.2.1. Secondary Care Hospitals
    • 10.2.2. Tertiary Care Hospitals
  • 10.3. Research Institutes

11. Adult Hemoglobinopathy Testing Market, by Distribution Channel

  • 11.1. Direct Sales
  • 11.2. Distributors
    • 11.2.1. Local Distributors
    • 11.2.2. Regional Distributors
  • 11.3. Online Vendors

12. Adult Hemoglobinopathy Testing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Adult Hemoglobinopathy Testing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Adult Hemoglobinopathy Testing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Roche Diagnostics International AG
    • 15.3.2. Thermo Fisher Scientific Inc.
    • 15.3.3. Siemens Healthineers AG
    • 15.3.4. Abbott Laboratories
    • 15.3.5. Bio-Rad Laboratories, Inc.
    • 15.3.6. Ortho Clinical Diagnostics Inc.
    • 15.3.7. Danaher Corporation
    • 15.3.8. Becton, Dickinson and Company
    • 15.3.9. PerkinElmer, Inc.
    • 15.3.10. Sysmex Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. ADULT HEMOGLOBINOPATHY TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. ADULT HEMOGLOBINOPATHY TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ADULT HEMOGLOBINOPATHY TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY ELECTROPHORESIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY ELECTROPHORESIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY ELECTROPHORESIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY ELECTROPHORESIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY ELECTROPHORESIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY ELECTROPHORESIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GENETIC ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GENETIC ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GENETIC ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GENETIC ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GENETIC ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GENETIC ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY POINT OF CARE TESTS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY POINT OF CARE TESTS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY POINT OF CARE TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY POINT OF CARE TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY POINT OF CARE TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY POINT OF CARE TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY POINT OF CARE TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY POINT OF CARE TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY RAPID TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY RAPID TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY RAPID TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY RAPID TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY RAPID TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY RAPID TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HEMOGLOBIN C DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HEMOGLOBIN C DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HEMOGLOBIN C DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HEMOGLOBIN C DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HEMOGLOBIN C DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HEMOGLOBIN C DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY SICKLE CELL DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY SICKLE CELL DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY SICKLE CELL DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY SICKLE CELL DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY SICKLE CELL DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY SICKLE CELL DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY ALPHA THALASSEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY ALPHA THALASSEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY ALPHA THALASSEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY ALPHA THALASSEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY ALPHA THALASSEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY ALPHA THALASSEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY BETA THALASSEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY BETA THALASSEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY BETA THALASSEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY BETA THALASSEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY BETA THALASSEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY BETA THALASSEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DELTA THALASSEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DELTA THALASSEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DELTA THALASSEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DELTA THALASSEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DELTA THALASSEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DELTA THALASSEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY SECONDARY CARE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY SECONDARY CARE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY SECONDARY CARE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY SECONDARY CARE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY SECONDARY CARE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY SECONDARY CARE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIRECT SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTORS, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTORS, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LOCAL DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LOCAL DISTRIBUTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LOCAL DISTRIBUTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LOCAL DISTRIBUTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LOCAL DISTRIBUTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LOCAL DISTRIBUTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REGIONAL DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REGIONAL DISTRIBUTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REGIONAL DISTRIBUTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REGIONAL DISTRIBUTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REGIONAL DISTRIBUTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REGIONAL DISTRIBUTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY ONLINE VENDORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY ONLINE VENDORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY ONLINE VENDORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY ONLINE VENDORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY ONLINE VENDORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY ONLINE VENDORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY POINT OF CARE TESTS, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY POINT OF CARE TESTS, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTORS, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTORS, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY POINT OF CARE TESTS, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY POINT OF CARE TESTS, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTORS, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTORS, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY POINT OF CARE TESTS, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY POINT OF CARE TESTS, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTORS, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTORS, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY POINT OF CARE TESTS, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY POINT OF CARE TESTS, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTORS, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTORS, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY POINT OF CARE TESTS, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY POINT OF CARE TESTS, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE ADULT HEMOGLOBI